Original Article
Wavefront-guided Photorefractive Keratectomy With the VISX Platform for Myopia
Simon R. Bababeygy, MD; Edward E. Manche, MD
Journal of Refractive Surgery
March 2011 - Volume 27 · Issue 3: 173-180
DOI: 10.3928/1081597X-20100527-01
PURPOSE
To evaluate the safety, efficacy, and clinical outcome of
wavefront-guided photorefractive keratectomy (PRK) for the treatment of low to
moderate and high myopia and compound myopic astigmatism.
METHODS
This retrospective study included 174 eyes of 102 patients with low to
moderate (–0.125 to <–6.50 diopters [D]) and high (>6.50 D) myopia treated with wavefront-guided PRK using the VISX
CustomVue S4 IR (Abbott Medical Optics) excimer laser. Eyes were analyzed
preoperatively and at 1, 3, 6, and 12 months postoperatively. At 3 months, 174
eyes of 102 patients were evaluated, and at 12 months, 146 eyes of 75 patients
were evaluated. No eyes were retreated in the study.
RESULTS
Mean patient age was 38.3±8.76 years (range: 20 to 66 years), and
mean preoperative manifest refraction spherical equivalent (MRSE) was
–5.60±2.58 D (range: –0.13 to –10.50 D). At 12 months
postoperative, MRSE was –0.16±0.45 D (range: –1.50 to 1.38 D);
96.6% of eyes were within ±1.00 D of intended correction, whereas 81.5%
were within ±0.50 D of intended correction. For all eyes, the safety and
efficacy indexes were 1.01 and 1.02, respectively.
CONCLUSIONS
These data support the safety and efficacy for the correction of low to
moderate and high myopia and compound myopic astigmatism using wavefront-guided
PRK. [J Refract Surg. 2011;27(3):173-180.]
doi:10.3928/1081597X-20100527-01
AUTHORS
From the Department of Ophthalmology (Bababeygy, Manche) and Howard
Hughes Medical Institute (Bababeygy), Stanford University School of Medicine,
Stanford; and Doheny Eye Institute and the Department of Ophthalmology, Keck
School of Medicine, University of Southern California, Los Angeles (Bababeygy),
California.
The authors have no proprietary or financial interest in the materials
presented herein.
Correspondence: Edward E. Manche, MD, Stanford University School of
Medicine, Dept of Ophthalmology, 900 Blake Wilbur Dr, Room W3002, Stanford, CA
94305. Tel: 650.723.6661; Fax: 650.723.6619; E-mail:
Edward.Manche@stanford.edu
Received: December 4, 2009; Accepted: April 30, 2010
Posted online: June 15, 2010
You may also like to read: